A Study to Evaluate Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy

ID#: NCT06253221

Age: 12 - 17 years

Gender: All

Healthy Subjects: No

Study Phase: Phase 3

Recruitment Status: Recruiting

Start Date: April 17, 2024

End Date: March 29, 2030

Contact Information:
BMS Study Connect Contact Center www.BMSStudyConnect.com
855-907-3286
First line of the email MUST contain the NCT# and Site #.
Summary: The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of mavacamten in adolescent patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM).
Eligibility:

Inclusion Criteria:

- Diagnosis of HCM

- Presence of LVOT obstruction

- Presence of symptoms

Exclusion Criteria:

- Phenocopy diseases resulting in myocardial hypertrophy not related to sarcomere dysfunction

- Evidence of LVEF <50% in prior 6 months

- Planned escalation in HCM therapy or upcoming intervention (eg, major cardiac surgery, HCM medication dose increase) Other protocol-defined Inclusion/Exclusion criteria apply.
Find a Clinical Trial Find Cancer Clinical Trials